Swedish Orphan Biovitrum AB (publ) operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Swedish Orphan Biovitrum AB (publ) with three other
pharmaceutical manufacturers in Europe:
sales of 885.38 million Bulgarian Lev [US$551.64 million]
of which 51%
of the United Kingdom
(£447.50 million [US$618.95 million]
of which 37%
was Licensing), and
Recipharm AB (publ)
(4.68 billion Swedish Kronor [US$581.09 million]
of which 43%
Swedish Orphan Biovitrum AB (publ) reported sales of SEK 4.50 billion (US$558.49 million)
December of 2016.
increase of 39.3%
versus 2015, when the company's sales were SEK 3.23 billion.
Sales at Swedish Orphan Biovitrum AB (publ) have increased during each of the previous five years
(and since 2011, sales have increased a total of 135%).
Sales of Core Products/kineret saw an increase
24.3% in 2016, from
SEK 805.36 million to SEK 1.00 billion.
Not all segments of Swedish Orphan Biovitrum AB (publ) experienced an increase in sales in 2016:
sales of Royalty-Refacto fell 43.6% to SEK 88.00 million.
(However, this segment's sales were only a very small portion of the company's overall sales).
Swedish Orphan Biovitrum AB (publ) also experienced decreases in sales in
Core Products/orfadin (down 3.2% to SEK 770.00 million)
Other Core Products (down 26.9% to SEK 105.00 million)